Identify the publications being discussed
Hoffer and colleagues published Treatment of schizophrenia with nicotinic acid and nicotinamide in 1957. Hoffer later published Megavitamin B-3 therapy for schizophrenia in 1971. The bibliographic records establish the papers and their dates; the 1957 PubMed entry does not provide an abstract from which to infer additional trial details. [1] [2]
Keep deficiency biology in view
Niacin is an essential nutrient. Severe deficiency causes pellagra, which can include neurological and psychiatric manifestations. Recognizing that established deficiency condition does not by itself validate niacin as a general treatment for schizophrenia or other psychiatric diagnoses. These are separate clinical questions with different evidence requirements. [3]
Read historical claims in context
Hoffer's work is central to the history of the orthomolecular movement, but a paper's historical importance and a current treatment recommendation are different judgments. Study design, comparison groups, outcomes and later replication all matter when assessing what an early report can support. [1] [2]
Treat high-dose use as a clinical question
Pharmacological niacin use can cause important adverse effects, including liver injury. This guide offers sources for understanding the history rather than a supplement protocol. Decisions involving psychiatric care or high-dose niacin require qualified clinical supervision, including attention to existing treatment and monitoring. [3]
These notes explain sources and testing context. They do not diagnose a condition, select a personal supplement dose or replace professional medical advice.